Nature Communications (Nov 2022)
CD8+ T cell differentiation status correlates with the feasibility of sustained unresponsiveness following oral immunotherapy
- Abhinav Kaushik,
- Diane Dunham,
- Xiaorui Han,
- Evan Do,
- Sandra Andorf,
- Sheena Gupta,
- Andrea Fernandes,
- Laurie Elizabeth Kost,
- Sayantani B. Sindher,
- Wong Yu,
- Mindy Tsai,
- Robert Tibshirani,
- Scott D. Boyd,
- Manisha Desai,
- Holden T. Maecker,
- Stephen J. Galli,
- R. Sharon Chinthrajah,
- Rosemarie H. DeKruyff,
- Monali Manohar,
- Kari C. Nadeau
Affiliations
- Abhinav Kaushik
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Diane Dunham
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Xiaorui Han
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Evan Do
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Sandra Andorf
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Sheena Gupta
- Human Immune Monitoring Center, Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine
- Andrea Fernandes
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Laurie Elizabeth Kost
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Sayantani B. Sindher
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Wong Yu
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Mindy Tsai
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Robert Tibshirani
- Department of Biomedical Data Science, Stanford University
- Scott D. Boyd
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Manisha Desai
- Department of Biomedical Data Science, Stanford University
- Holden T. Maecker
- Human Immune Monitoring Center, Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine
- Stephen J. Galli
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- R. Sharon Chinthrajah
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Rosemarie H. DeKruyff
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Monali Manohar
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- Kari C. Nadeau
- Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-34222-8
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
Oral immunotherapy (OIT) clinical trials have helped a subset of participants achieve sustained unresponsiveness (SU) to the cognate allergen. Here the authors analyse immune cells from participants from one peanut OIT trial and show that CD8+ T cell differentiation status at baseline may help to predict the likelihood of achieving SU.
